Physician profile
Ted A Dunn
NPI 1578527768
$2,995.95
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $756 · 2020: $507 · 2021: $57.98 · 2022: $794 · 2023: $881.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $881.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $880.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $380.97 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $325.85 | 2019-2023 | Xifaxan |
| Lilly USA, LLC | $262.03 | 2019-2023 | Mounjaro, Trulicity |
| Abbvie INC. | $244.41 | 2019-2023 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $234.79 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $155.58 | 2022-2023 | Trintellix |
| Allergan, INC. | $130.90 | 2019-2020 | |
| Pfizer INC. | $127.76 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $114.95 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $109.27 | 2019-2021 | |
| Exact Sciences Corporation | $107.87 | 2023 | Cologuard Collection Kit |
| Amgen INC. | $93.21 | 2019-2023 | Otezla, Repatha |
| Esperion Therapeutics, INC. | $67.17 | 2020-2023 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.18 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $62.29 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $54.90 | 2022-2023 | Hetlioz |
| Shire North American Group INC | $53.87 | 2019 | |
| Amarin Pharma, INC. | $51.98 | 2019-2020 | |
| Abbott Laboratories | $49.11 | 2022 | |
| Janssen Pharmaceuticals, INC | $42.18 | 2021-2022 | |
| Astellas Pharma US INC | $37.45 | 2023 | Myrbetriq, Veozah |
| Phadia US INC. | $34.17 | 2019-2022 | |
| Daiichi Sankyo INC. | $26.40 | 2019 | |
| Dexcom, INC. | $24.90 | 2023 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $23.15 | 2019-2020 | |
| Mannkind Corporation | $19.68 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $17.97 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $17.85 | 2022 | |
| Hologic Sales and Service, LLC | $13.30 | 2019 | |
| Glaxosmithkline, LLC. | $13.07 | 2020 | |
| Merck Sharp & Dohme LLC | $12.66 | 2019 | |
| Boston Scientific Corporation | $11.08 | 2019 | |
| Neuronetics, INC. | $10.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ted Dunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.